174 related articles for article (PubMed ID: 12116365)
1. Flow cytometric analysis of breast cancer resistance protein expression and function.
Minderman H; Suvannasankha A; O'Loughlin KL; Scheffer GL; Scheper RJ; Robey RW; Baer MR
Cytometry; 2002 Jun; 48(2):59-65. PubMed ID: 12116365
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
Scheffer GL; Maliepaard M; Pijnenborg AC; van Gastelen MA; de Jong MC; Schroeijers AB; van der Kolk DM; Allen JD; Ross DD; van der Valk P; Dalton WS; Schellens JH; Scheper RJ
Cancer Res; 2000 May; 60(10):2589-93. PubMed ID: 10825126
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival.
Suvannasankha A; Minderman H; O'Loughlin KL; Nakanishi T; Ford LA; Greco WR; Wetzler M; Ross DD; Baer MR
Br J Haematol; 2004 Nov; 127(4):392-8. PubMed ID: 15521915
[TBL] [Abstract][Full Text] [Related]
4. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
Maliepaard M; Scheffer GL; Faneyte IF; van Gastelen MA; Pijnenborg AC; Schinkel AH; van De Vijver MJ; Scheper RJ; Schellens JH
Cancer Res; 2001 Apr; 61(8):3458-64. PubMed ID: 11309308
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
6. Expression and functional analyses of breast cancer resistance protein in lung cancer.
Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.
Suvannasankha A; Minderman H; O'Loughlin KL; Nakanishi T; Greco WR; Ross DD; Baer MR
Leukemia; 2004 Jul; 18(7):1252-7. PubMed ID: 15208643
[TBL] [Abstract][Full Text] [Related]
8. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.
van der Kolk DM; Vellenga E; Scheffer GL; Müller M; Bates SE; Scheper RJ; de Vries EG
Blood; 2002 May; 99(10):3763-70. PubMed ID: 11986234
[TBL] [Abstract][Full Text] [Related]
9. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
Gupta A; Dai Y; Vethanayagam RR; Hebert MF; Thummel KE; Unadkat JD; Ross DD; Mao Q
Cancer Chemother Pharmacol; 2006 Sep; 58(3):374-83. PubMed ID: 16404634
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia.
Raaijmakers MH; de Grouw EP; Heuver LH; van der Reijden BA; Jansen JH; Scheper RJ; Scheffer GL; de Witte TJ; Raymakers RA
Clin Cancer Res; 2005 Mar; 11(6):2436-44. PubMed ID: 15788695
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
[TBL] [Abstract][Full Text] [Related]
14. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
Shepard RL; Cao J; Starling JJ; Dantzig AH
Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
[TBL] [Abstract][Full Text] [Related]
15. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
16. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
17. A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2).
Mahringer A; Delzer J; Fricker G
Eur J Pharm Biopharm; 2009 Aug; 72(3):605-13. PubMed ID: 19572416
[TBL] [Abstract][Full Text] [Related]
18. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Honjo Y; Hrycyna CA; Yan QW; Medina-Pérez WY; Robey RW; van de Laar A; Litman T; Dean M; Bates SE
Cancer Res; 2001 Sep; 61(18):6635-9. PubMed ID: 11559526
[TBL] [Abstract][Full Text] [Related]
19. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
20. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
Volk EL; Schneider E
Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
